Key Highlights
- GSK is purchasing Nuvalent in an all-cash transaction valued at $10.6 billion, paying $124 per share
- The acquisition price reflects a 40% premium above Monday’s market close
- Shares of Nuvalent surged 39% to reach $122.90 during Tuesday’s early market session
- GSK acquires three lung cancer treatment programs, with two pending FDA regulatory reviews in late 2026
- This represents GSK’s most substantial acquisition in more than ten years
British pharmaceutical giant GSK revealed plans Tuesday to purchase Boston-headquartered oncology specialist Nuvalent for $10.6 billion in an all-cash transaction, propelling Nuvalent shares 39% higher to $122.90.
The $124-per-share acquisition price delivers a substantial 40% premium compared to Nuvalent’s Monday closing value. GSK’s American depositary receipts held steady at $50.65, though its London-traded shares fell over 3%.
This transaction represents GSK’s most significant acquisition in more than a decade and signals a dramatic strategic realignment for the pharmaceutical powerhouse.
The acquisition brings GSK ownership of three non-small cell lung cancer treatment candidates. The portfolio’s flagship assets include zidesamtinib, designed to target ROS1 mutations, and neladalkib, which functions as an ALK inhibitor.
Both leading compounds have advanced to late-stage clinical development and are currently undergoing FDA evaluation. The regulatory agency is scheduled to render decisions on September 18 and November 27, 2026, for the respective treatments.
A third compound, NVL-330, represents a HER2 inhibitor presently in phase I clinical trials.
“These two leading products represent potentially best-in-class therapies that could receive market authorization this year pending FDA approval,” stated GSK CEO Luke Miels.
GSK’s Strategic Return to Cancer Treatment
GSK previously divested its oncology portfolio to Novartis in 2014 as part of an asset exchange that brought Novartis’ vaccine business to GSK. The current transaction signals an emphatic re-entry into cancer therapeutics as a strategic priority.
Miels, who assumed the CEO position in early 2026, had previously communicated to stakeholders a focus on acquisitions ranging between £2 billion and £4 billion. He defended the elevated price point by emphasizing that the transaction effectively secures three separate products in a single deal.
After accounting for acquired cash positions, GSK’s net investment totals approximately $9.4 billion. The company plans to finance the acquisition through a combination of new and existing credit facilities plus available cash reserves, anticipating no adverse effect on its credit rating.
Financial Impact on GSK
GSK confirmed its current 2026 full-year financial projections remain intact. The pharmaceutical company anticipates the acquisition will begin contributing to revenue growth and core operating profit starting in 2027, with meaningful core earnings per share accretion materializing in 2029.
GSK indicated the transaction will help bolster core operating profit during the anticipated dolutegravir exclusivity loss period spanning 2028 through 2030.
The deal is positioned to expedite GSK’s establishment in the lung cancer market and establish a foundation for additional expansion alongside Ris-Rez, its B7-H3 antibody-drug conjugate currently advancing through phase III clinical studies.
Pending regulatory clearances, including approval under Hart-Scott-Rodino antitrust regulations, both organizations anticipate finalizing the transaction prior to the conclusion of Q3 2026.
The FDA’s determinations regarding Nuvalent’s two primary drug candidates are set for September 18 and November 27, 2026.
